JPH10508614A - 飽和溶解度と溶解速度を増大させた薬剤投与用ナノ懸濁液 - Google Patents
飽和溶解度と溶解速度を増大させた薬剤投与用ナノ懸濁液Info
- Publication number
- JPH10508614A JPH10508614A JP8515711A JP51571196A JPH10508614A JP H10508614 A JPH10508614 A JP H10508614A JP 8515711 A JP8515711 A JP 8515711A JP 51571196 A JP51571196 A JP 51571196A JP H10508614 A JPH10508614 A JP H10508614A
- Authority
- JP
- Japan
- Prior art keywords
- carrier
- drug
- particles
- nanosuspension
- particle size
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.水に不溶性もしくは難溶性の純粋な活性化合物の粒子、または室温で固体 状の2種もしくはそれ以上の活性成分の混合物であって平均粒径[光子相関分光 分析(PCS)による値]が10〜1000nmでありかつ平均粒径が5μmよりも大 きな粒子の全母集団中の割合(クールター計数器によって測定する数分布)が0. 1%よりも少ない粒子を含有する薬剤キャリヤー。 2.水または水性液体中に導入したときに、薬剤の飽和溶解度と溶解速度が粉 状形態の場合に比べて増大する請求項1記載のキャリヤー。 3.主母集団の粒子が40〜1000nm(特に、100〜800nm)の平均粒径 、適当に選択されたプロセスパラメーターおよび40〜100nmの助剤を有する 請求項1記載のキャリヤー。 4.キャビテーション(例えば、ピストンギャップホモジナイザー)によって調 製される請求項1記載のキャリヤー。 5.剪断力および衝撃力(即ち、ジェットストリーム原理)によって調製される 請求項1記載のキャリヤー。 6.界面活性剤の不存在下または0.001〜30%、特に1.0%以下、就中 、0.5%以下の合成、半合成もしくは天然の界面活性剤[例えば、レシチンもし くは分別精製レシチンまたはこれらの混合物]あるいは1種もしくは2種以上の 安定剤と混合した界面活性剤を用いて調製される請求項1記載のキャリヤー。 7.有機溶剤を使用しないで調製される請求項1記載のキャリヤー。 8.超音波プローブ、ボールミルまたはパールミルを使用しないで調製される 請求項1記載のキャリヤー。 9.内部相もしくは薬剤相の含有量(基本処方成分に基づく値)が0.1〜30w t%、特に1〜20wt%である請求項1から8いずれかに記載のキャリヤー。 10.薬剤キャリヤーが水もしくは水性溶液に微溶性もしくは不溶性の活性化合 物を1種もしくは2種以上含有する請求項1から9いずれかに記載のキャリヤー 。 11.薬剤キャリヤーが有機溶剤に微溶性もしくは不溶性の活性化合物を1種も しくは2種以上含有する請求項1から9いずれかに記載のキャリヤー。 12.薬剤キャリヤーが水もしくは水性溶液および有機溶剤に微溶性もしくは不 溶性の活性成分を1種もしくは2種以上含有する請求項1から9いずれかに記載 のキャリヤー。 13.薬剤キャリヤーが水もしくは水性溶液および/または有機溶剤に対して適 度な溶解性を示す活性化合物を1種もしくは2種以上含有する請求項1から8い ずれかに記載のキャリヤー。 14.分散安定剤を1種もしくは2種以上含有する請求項1から13いずれかに 記載のキャリヤー。 15.分散安定剤の含有量(基本処方成分に基づく値)が0.001〜20wt%、 特に0.01〜5wt%である請求項14記載のキャリヤー。 16.分散安定剤が下記の群から選択される1種もしくは2種以上の混合物であ る請求項14または15記載のキャリヤー:ポロキサマー、ポロキサン、エトキ シル化モノ−もしくはジグリセリド、エトキシル化脂質およびリポイド、エトキ シル化脂肪アルコールおよびアルキルフェノール、エトキシル化脂肪酸エステル 、ポリグリセロールエーテルおよびエステル、レシチン、脂肪酸もしくは脂肪ア ルコールと糖もしくは糖アルコールとのエステルおよびエーテル、ホスホリピド およびスフィンゴリピド、ステロールおよびそのエステルもしくはエーテル。 17.分散安定剤が卵レシチン、大豆レシチンもしくは水素化レシチン、これら の混合物、これらレシチンの一方もしくは両方と1種もしくは2種以上ホスホリ ピド化合物、コレステロール、コレステロールパルミテート、スチグマステロー ルもしくは他のステロイドとの混合物である請求14、15または16記載のキ ャリヤー。 18.電荷安定剤を含有する請求項1から17いずれかに記載のキャリヤー。 19.電荷安定剤の含有量(基本処方成分に基づく値)が0.01〜20wt%、特 に0.01〜2wt%である請求項18記載のキャリヤー。 20.電荷安定剤がジセチルホスフェート、ホスファチジルグリセロール、飽和 もしくは不飽和脂肪酸、コール酸ナトリウム、抗凝集剤またはアミノ酸を含有す る請求項18または19記載のキャリヤー。 21.1種または2種以上の粘度上昇剤を含有する請求項1から13いずれかに 記載のキャリヤー。 22.粘度上昇剤の含有量(基本処方成分に基づく値)が0.1〜20wt%、特に 0.5〜5wt%である請求項21記載のキャリヤー。 23.粘度上昇剤がセルロースエーテルおよびエステル、ポリビニル誘導体、ポ リビニルアルコール、アルギネート、キサンタン、ペクチン、ポリアクリレート 、ポロキサマーおよびポロキサミンを含有する請求項21または22記載のキャ リヤー。 24.糖または糖アルコール、特にグルコース、マンノース、トレハロース、マ ンニトールおよびソルビトールを含有する請求項21から23いずれかに記載の キャリヤー。 25.電荷キャリヤーを含有する請求項21から24いずれかに記載のキャリヤ ー。 26.粒子を蒸留水、水性媒体、または電解質、モノ−もしくはジサッカリド、 ポリオールもしくはこれらの混合物を添加した水性媒体に分散させた請求項1か ら25いずれかに記載のキャリヤー。 27.添加剤が塩化ナトリウム、マンノース、グルコース、フルクトース、キシ ロース、マンニトール、ソルビトール、キシリトールおよびグリセロールを含有 する請求項26記載のキャリヤー。 28.粒子が凍結乾燥または噴霧乾燥された請求項1から27いずれかに記載の キャリヤー。 29.1種もしくは数種の活性化合物を含有する請求項1から28いずれかに記 載のキャリヤー。 30.数種の活性化合物を含有する場合、1種もしくは数種の活性化合物を1種 もしくは数種の他の活性化合物に溶解(固溶体)もしくは分散させるか(固体分散 体)、あるいはこれらの表面上に吸着させるか、または粒子中に分散させる請求 項29記載のキャリヤー。 31.非水媒体中に分散された請求項1から25いずれかに記載のキャリヤー。 32.液体、半固体または固体媒体中に分散された請求項31記載のキャリヤー 。 33.液状油性媒体、例えばヒマシ油、アメリカホドイモ油、オリーブ油、中性 油(ミグリオール812)、ゴマ油、トウモロコシ油、綿実油、アーモンド油、中 鎖トリグリセリドまたはその他の油中に分散された請求項32記載のキャリヤー 。 34.媒体が脂質もしくはリポイドまたはこれらの混合物を含有する請求項32 記載のキャリヤー。 35.媒体がモノ−、ジ−もしくはトリグリセリド(例えば、ワイテプソール、 ソフチサン)、ワックス、脂肪アルコール、脂肪アルコールエステル、蜜ろう、 オレイルオレエート、イソプロピルミリステート、羊毛脂またはこれらの混合物 を含有する請求項34記載のキャリヤー。 36.媒体が長鎖有機分子もしくはポリマー、液状、半固体状もしくは固体状ポ リエチレングリコール、ポロキサマー、ポロキサミンまたはこれらの混合物を含 有する請求項32記載のキャリヤー。 37.下記の工程(i)〜(iii)を含む請求項1から4および6〜36いずれかに記 載の薬剤キャリヤーの製造法: (i)単一の薬剤または薬剤混合物を粉末に粉砕し、 (ii)該粉末を分散剤(水または水性媒体)中に分散させ、 (iii)該分散液をキャビテーション発生装置、例えば、ピストンギャップホモ ジナイザー(例えば、APVゴーリン社(リューベック、ドイツ)製装置)またはフ レンチプレス[SLMインストゥルメンツ社(アーバナ、イリノイ、米国)製]を用 いてギャップ間を加圧下で強制通過させる。 38.下記の工程(i)〜(iii)を含む請求項1〜3および5〜36いずれかに記載 の薬剤キャリヤーの製造法: (i)単一の薬剤または薬剤混合物を粉末に粉砕し、 (ii)該粉末の分散剤(水または水性媒体)中に分散させ、 (iii)該分散液を例えばミクロ流動化装置(ミクロフルイディックス社(ニュー トン、マサーチューセッツ、米国)製)またはナノジェット(ナノジェット・エン ジニアリング社(44339ドルトムント、独国)製)を用いて湿潤状態、即ちジ ェットストリーム状態で粉砕する。 39.請求項1から38いずれかに記載の薬剤キャリヤーを医薬活性化合物の投 与のために使用する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4440337.2 | 1994-11-11 | ||
DE4440337A DE4440337A1 (de) | 1994-11-11 | 1994-11-11 | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
PCT/EP1995/004401 WO1996014830A1 (de) | 1994-11-11 | 1995-11-09 | Pharmazeutische nanosuspensionen zur arzneistoffapplikation als systeme mit erhöhter sättigungslöslichkeit und lösungsgeschwindigkeit |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10508614A true JPH10508614A (ja) | 1998-08-25 |
JP3977418B2 JP3977418B2 (ja) | 2007-09-19 |
Family
ID=6533079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51571196A Expired - Lifetime JP3977418B2 (ja) | 1994-11-11 | 1995-11-09 | 飽和溶解度と溶解速度を増大させた薬剤投与用ナノ懸濁液 |
Country Status (19)
Country | Link |
---|---|
US (1) | US5858410A (ja) |
EP (1) | EP0790821B1 (ja) |
JP (1) | JP3977418B2 (ja) |
KR (1) | KR100480447B1 (ja) |
CN (1) | CN1210018C (ja) |
AT (1) | ATE278387T1 (ja) |
AU (1) | AU714978B2 (ja) |
CA (1) | CA2205046C (ja) |
CZ (1) | CZ293253B6 (ja) |
DE (3) | DE4440337A1 (ja) |
EE (1) | EE9700217A (ja) |
ES (1) | ES2229242T3 (ja) |
FI (1) | FI119465B (ja) |
HU (1) | HU228097B1 (ja) |
MX (1) | MX9703399A (ja) |
NO (1) | NO323143B1 (ja) |
PL (1) | PL320085A1 (ja) |
SK (1) | SK284541B6 (ja) |
WO (1) | WO1996014830A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003504323A (ja) * | 1999-07-13 | 2003-02-04 | ファルマソル ゲーエムベーハー | 超微細マイクロ粒子およびナノ粒子の制御された製造方法。 |
JP2003527411A (ja) * | 2000-03-23 | 2003-09-16 | コラボレイティヴ・テクノロジーズ・インコーポレーテッド | 生理学上活性な成分を含有する高圧/高剪断分散物を調製する方法 |
WO2006073154A1 (ja) * | 2005-01-07 | 2006-07-13 | Eisai R&D Management Co., Ltd. | 医薬組成物及びその製造方法 |
JP2008536812A (ja) * | 2005-03-11 | 2008-09-11 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 超微細サブミクロン懸濁液の製造方法 |
JP2008544963A (ja) * | 2005-06-29 | 2008-12-11 | ディーエスエム アイピー アセッツ ビー.ブイ. | イソフラボンナノ粒子およびその使用 |
JP2009503074A (ja) * | 2005-08-02 | 2009-01-29 | セラムオプテック インダストリーズ インコーポレーテッド | セルライトに対する光力学療法および美容法 |
JP2011513258A (ja) * | 2008-02-29 | 2011-04-28 | シュリフトハール ライナー | 改善された不純物プロファイル及び安全性を有し、吸入により投与される抗真菌薬を有するナノ懸濁液 |
JP2013501051A (ja) * | 2009-08-06 | 2013-01-10 | 株式会社エービーサイズ | ナノ粒子の溶液およびナノ粒子の懸濁物の両者を有する局所用薬学的調製物ならびに該調製物をもって急性疼痛および慢性疼痛を処置する方法 |
JP2013525385A (ja) * | 2010-04-27 | 2013-06-20 | 重▲慶▼莱美▲薬▼▲業▼股▲分▼有限公司 | ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法 |
JP2013209422A (ja) * | 2001-10-12 | 2013-10-10 | Elan Pharma Internatl Ltd | 即時放出および徐放特性を組み合わせて有する組成物 |
WO2015068397A1 (ja) * | 2013-11-08 | 2015-05-14 | 株式会社アクティバスファーマ | マクロライド系抗菌剤のナノ微粒子を含有する水性懸濁液剤 |
Families Citing this family (199)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE274341T1 (de) * | 1995-02-24 | 2004-09-15 | Elan Pharma Int Ltd | Nanopartikel-dispersionen enthaltende aerosole |
US6465016B2 (en) | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
GB9625589D0 (en) * | 1996-12-10 | 1997-01-29 | Boots Co Plc | Therapeutic agents |
JP3821407B2 (ja) * | 1997-06-26 | 2006-09-13 | 富士写真フイルム株式会社 | 感光性画像形成媒体塗布液の製造方法および熱現像感光材料 |
US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
US6432986B2 (en) | 1997-07-21 | 2002-08-13 | Bruce H. Levin | Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
US6045815A (en) * | 1997-08-15 | 2000-04-04 | Board Of Regents, The University Of Texas System | Parenteral pimaricin as treatment of systemic infections |
US6844004B2 (en) * | 1997-08-15 | 2005-01-18 | Board Of Regents, The University Of Texas System | Topical formulations of natamycin/pimaricin |
GB9718568D0 (en) | 1997-09-03 | 1997-11-05 | Chauvin Pharmaceuticals Limite | Compositions |
WO1999012571A1 (fr) * | 1997-09-05 | 1999-03-18 | Maruho Kabushikikaisha | Preparations de nanocapsules destinees au traitement de maladies intra-articulaires |
CN1156277C (zh) * | 1997-10-20 | 2004-07-07 | 大日本制药株式会社 | 速溶性药用组合物 |
WO1999031987A1 (en) * | 1997-12-19 | 1999-07-01 | Taro Pharmaceuticals U.S.A., Inc. | Topical carbamazepine formulations and methods of use |
US6287693B1 (en) * | 1998-02-25 | 2001-09-11 | John Claude Savoir | Stable shaped particles of crystalline organic compounds |
US6337092B1 (en) | 1998-03-30 | 2002-01-08 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
CN1303278B (zh) | 1998-03-30 | 2010-06-23 | 斯凯伊药品加拿大公司 | 制备水不溶性物质微粒的组合物和方法 |
US7381423B2 (en) * | 1998-05-11 | 2008-06-03 | Ciba Specialty Chemicals Corp. | Use of nanodispersions in cosmetic end formulations |
WO1999061001A1 (en) | 1998-05-29 | 1999-12-02 | Rtp Pharma Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
DE69912441T2 (de) * | 1998-08-19 | 2004-08-19 | Skyepharma Canada Inc., Verdun | Injizierbare wässerige propofoldispersionen |
US20040013613A1 (en) * | 2001-05-18 | 2004-01-22 | Jain Rajeev A | Rapidly disintegrating solid oral dosage form |
WO2000021490A1 (de) * | 1998-10-14 | 2000-04-20 | Cognis Deutschland Gmbh | Verwendung von nanoskaligen sterolen und sterolestern |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
AU767154B2 (en) | 1998-11-20 | 2003-10-30 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
DE19856432A1 (de) | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
WO2000040219A1 (en) | 1998-12-30 | 2000-07-13 | Dexcel Ltd. | Dispersible concentrate for the delivery of cyclosporin |
AU4563100A (en) * | 1999-05-07 | 2000-11-21 | Pharmasol Gmbh | Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
CA2383233C (en) * | 1999-09-21 | 2010-06-08 | Rtp Pharma Inc. | Surface modified particulate compositions of biologically active substances |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
US20040009229A1 (en) * | 2000-01-05 | 2004-01-15 | Unger Evan Charles | Stabilized nanoparticle formulations of camptotheca derivatives |
US8404217B2 (en) * | 2000-05-10 | 2013-03-26 | Novartis Ag | Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use |
US6495164B1 (en) * | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
USRE44145E1 (en) | 2000-07-07 | 2013-04-09 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
DE10036871A1 (de) | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
US6623765B1 (en) * | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
CA2420597C (en) | 2000-08-31 | 2011-05-17 | Rtp Pharma Inc. | Milled particles |
DE10043509A1 (de) * | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
US8586094B2 (en) * | 2000-09-20 | 2013-11-19 | Jagotec Ag | Coated tablets |
US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
FR2817478A1 (fr) * | 2000-12-04 | 2002-06-07 | Oreal | Suspensions aqueuses de nanospheres de principes actifs lipophiles |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US6884436B2 (en) | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US6869617B2 (en) * | 2000-12-22 | 2005-03-22 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US9700866B2 (en) * | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US20040256749A1 (en) * | 2000-12-22 | 2004-12-23 | Mahesh Chaubal | Process for production of essentially solvent-free small particles |
US20050048126A1 (en) * | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US20110301569A1 (en) | 2001-01-20 | 2011-12-08 | Gordon Wayne Dyer | Methods and apparatus for the CVCS |
FR2820320B1 (fr) * | 2001-02-02 | 2003-04-04 | Oreal | Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles |
US20050215727A1 (en) | 2001-05-01 | 2005-09-29 | Corium | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
DE60233217D1 (de) | 2001-05-01 | 2009-09-17 | Corium Internat Inc | Hydrogel-zusammensetzungen |
WO2002087642A2 (en) * | 2001-05-01 | 2002-11-07 | A.V. Topchiev Institute Of Petrochemical Synthesis | Two-phase, water-absorbent bioadhesive composition |
US8206738B2 (en) | 2001-05-01 | 2012-06-26 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US20050113510A1 (en) | 2001-05-01 | 2005-05-26 | Feldstein Mikhail M. | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US8840918B2 (en) * | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US20030027833A1 (en) * | 2001-05-07 | 2003-02-06 | Cleary Gary W. | Compositions and delivery systems for administration of a local anesthetic agent |
US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
GB0114532D0 (en) * | 2001-06-14 | 2001-08-08 | Jagotec Ag | Novel compositions |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
US7163700B2 (en) * | 2001-07-31 | 2007-01-16 | Capricorn Pharma, Inc. | Amorphous drug beads |
US20080305173A1 (en) * | 2001-07-31 | 2008-12-11 | Beuford Arlie Bogue | Amorphous drug beads |
AU2002317409B2 (en) * | 2001-08-06 | 2007-06-21 | Astrazeneca Ab | Aqueous dispersion comprising stable nanoparticles of a water-insoluble active and an excipient like middle chain triglycerides (MCT) |
GB0119480D0 (en) | 2001-08-09 | 2001-10-03 | Jagotec Ag | Novel compositions |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
JP2005504090A (ja) * | 2001-09-26 | 2005-02-10 | バクスター・インターナショナル・インコーポレイテッド | 分散体および溶媒相または液相の除去によるサブミクロンサイズ−ナノ粒子の調製 |
US7906102B2 (en) | 2001-10-03 | 2011-03-15 | Vanderbilt University | Ligands to radiation-induced molecules |
WO2003032906A2 (en) * | 2001-10-15 | 2003-04-24 | Crititech, Inc. | Delivery of poorly soluble drugs |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
GB0127832D0 (en) * | 2001-11-20 | 2002-01-09 | Jagotec Ag | Method for the preparation of pharmaceutical nanosuspensions |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US20030129242A1 (en) * | 2002-01-04 | 2003-07-10 | Bosch H. William | Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
KR100422763B1 (ko) * | 2002-01-17 | 2004-03-12 | 주식회사 태평양 | 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물 |
EP1474144B1 (en) | 2002-02-01 | 2008-08-06 | Pfizer Products Inc. | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor |
CA2476556A1 (en) | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
WO2003070909A2 (en) * | 2002-02-20 | 2003-08-28 | Chiron Corporation | Microparticles with adsorbed polypeptide-containing molecules |
US20060280761A1 (en) * | 2002-03-11 | 2006-12-14 | Health Plus International, Inc. | Nanofluidized B-12 composition and process for treating pernicious anemia |
US6861066B2 (en) * | 2002-03-11 | 2005-03-01 | Health Plus International Inc. | Method for the delivery of a biologically active agent |
GB0216700D0 (en) * | 2002-07-18 | 2002-08-28 | Astrazeneca Ab | Process |
DE10234784A1 (de) * | 2002-07-30 | 2004-02-19 | Günenthal GmbH | Intravenös applizierbare, pharmazeutische Darreichungsform |
US7838034B2 (en) | 2002-07-30 | 2010-11-23 | Grunenthal Gmbh | Intravenous pharmaceutical form of administration |
CA2500661A1 (en) | 2002-10-01 | 2004-04-15 | Chiron Corporation | Anti-cancer and anti-infectious disease compositions and methods for using same |
US20040105778A1 (en) * | 2002-10-04 | 2004-06-03 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
BR0215979A (pt) * | 2002-12-13 | 2005-11-01 | Jagotec Ag | Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica |
GB0230087D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
JP2006513235A (ja) * | 2002-12-31 | 2006-04-20 | ネクター セラピューティクス | 真菌感染症療法のためのエアゾール化可能な医薬製剤 |
EP1589947B2 (en) * | 2002-12-31 | 2019-01-30 | Novartis AG | Pharmaceutical formulation with an insoluble active agent for pulmonary administration |
GB0302672D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302673D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
GB0302671D0 (en) * | 2003-02-06 | 2003-03-12 | Astrazeneca Ab | Pharmaceutical formulations |
SI1603513T1 (sl) | 2003-03-04 | 2021-04-30 | Lyotropic Therapeutics, Inc. | Sestavki dantrolena |
US7511079B2 (en) * | 2003-03-24 | 2009-03-31 | Baxter International Inc. | Methods and apparatuses for the comminution and stabilization of small particles |
WO2004105809A1 (en) * | 2003-05-22 | 2004-12-09 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
WO2004111033A1 (en) * | 2003-06-18 | 2004-12-23 | Astrazeneca Ab | 2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator. |
GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
GB0314261D0 (en) * | 2003-06-19 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
PE20050941A1 (es) * | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
AU2005206084A1 (en) * | 2004-01-09 | 2005-08-04 | Wyeth | Microemulsions for pharmaceutical compositions |
CN102764247B (zh) | 2004-01-30 | 2016-04-20 | 考里安国际公司 | 递送活性剂的快速溶解膜 |
WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
JP2008500288A (ja) * | 2004-05-28 | 2008-01-10 | イメイジノット ピーティーワイ エルティーディー | 経口治療用化合物の供給系 |
US8216610B2 (en) * | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
US20060160823A1 (en) * | 2004-05-28 | 2006-07-20 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmaceutical compositions of Posaconazole |
US20060009469A1 (en) * | 2004-05-28 | 2006-01-12 | Leonore Witchey-Lakshmanan | Particulate-stabilized injectable pharmacutical compositions of posaconazole |
US8513204B2 (en) * | 2004-06-21 | 2013-08-20 | Novartis Ag | Compositions comprising amphotericin B, mehods and systems |
CA2567785A1 (en) * | 2004-06-21 | 2006-01-05 | Nektar Therapeutics | Composition comprising amphotericin b methods and systems |
CA2572549A1 (en) * | 2004-07-01 | 2006-01-12 | Warner-Lambert Company Llc | Preparation of pharmaceutical compositions containing nanoparticles |
ES2526700T3 (es) * | 2004-08-05 | 2015-01-14 | Corium International, Inc. | Composición de adhesivo |
US20080171687A1 (en) * | 2004-09-16 | 2008-07-17 | Abraxis Bioscience, Inc. | Compositions And Methods For The Preparation And Administration Of Poorly Water Soluble Drugs |
ES2265262B1 (es) * | 2005-01-31 | 2008-03-01 | Activery Biotech, S.L.(Titular Al 50%) | Procedimiento para la obtencion de sistemas micro- y nanodispersos. |
CN101189001A (zh) * | 2005-02-15 | 2008-05-28 | 伊兰制药国际有限公司 | 纳米微粒苯并二氮杂䓬气雾剂及注射剂 |
EP1868574B1 (de) * | 2005-04-13 | 2010-01-06 | Abbott GmbH & Co. KG | Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung |
JP2009533314A (ja) * | 2005-04-13 | 2009-09-17 | ファイザー・プロダクツ・インク | ナノ粒子を含む貧溶性薬物を持続放出するための注射用デポ製剤および方法 |
US20070042049A1 (en) * | 2005-06-03 | 2007-02-22 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
EP1906973A2 (en) * | 2005-06-14 | 2008-04-09 | Baxter International Inc. | Pharmaceutical formulations for minimizing drug-drug interactions |
US20060280787A1 (en) * | 2005-06-14 | 2006-12-14 | Baxter International Inc. | Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof |
CA2618655C (en) * | 2005-07-18 | 2015-12-22 | University Of Massachusetts Lowell | Compositions and methods for making and using nanoemulsions |
DE102005053862A1 (de) * | 2005-11-04 | 2007-05-10 | Pharmasol Gmbh | Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel |
US20070134341A1 (en) * | 2005-11-15 | 2007-06-14 | Kipp James E | Compositions of lipoxygenase inhibitors |
CA2629904C (en) * | 2005-11-28 | 2018-07-10 | Imaginot Pty Ltd. | Oral therapeutic compound delivery system |
ES2710781T3 (es) | 2005-12-01 | 2019-04-26 | Univ Massachusetts Lowell | Nanoemulsiones de botulinum |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
US20080166411A1 (en) * | 2006-04-10 | 2008-07-10 | Pfizer Inc | Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles |
WO2008054508A2 (en) * | 2006-04-13 | 2008-05-08 | Alza Corporation | Stable nanosized amorphous drug |
WO2008002485A2 (en) * | 2006-06-23 | 2008-01-03 | Alza Corporation | Increased amorphous stability of poorly water soluble drugs by nanosizing |
US20100068251A1 (en) * | 2006-10-10 | 2010-03-18 | Jina Pharmaceuticals, Inc. | Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof |
CA2669392C (en) * | 2006-11-17 | 2016-05-10 | Abbott Gmbh & Co. Kg | Nanocrystals for use in topical cosmetic formulations and method of production thereof |
MX2009005726A (es) | 2006-12-01 | 2009-09-28 | Anterios Inc | Nanoparticulas peptidicas y usos de las mismas. |
EP2099429A2 (en) | 2006-12-01 | 2009-09-16 | Anterios, Inc. | Micellar nanoparticles comprising botulinum toxin |
US20090152176A1 (en) * | 2006-12-23 | 2009-06-18 | Baxter International Inc. | Magnetic separation of fine particles from compositions |
DE102007001473A1 (de) | 2007-01-08 | 2008-07-10 | Andreas Lemke | Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck |
KR100907877B1 (ko) * | 2007-03-15 | 2009-07-14 | 윤의식 | 금속 나노입자 콜로이드 용액 제조 방법 및 이를 이용한 금속 나노입자 분말 제조 방법 |
US8426467B2 (en) * | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) * | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
US20080293814A1 (en) * | 2007-05-22 | 2008-11-27 | Deepak Tiwari | Concentrate esmolol |
CN101765423B (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
US20110097410A1 (en) * | 2007-08-24 | 2011-04-28 | Berney Richard L | Formulations of px compounds |
BRPI0820745A2 (pt) * | 2007-12-13 | 2015-06-16 | Novartis Ag | Compostos orgânicos |
HU230862B1 (hu) * | 2008-04-28 | 2018-10-29 | DARHOLDING Vagyonkezelő Kft | Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására |
BRPI0913021A2 (pt) * | 2008-05-15 | 2015-10-13 | Novartis Ag | distribuição pulmonar de uma fluoroquinolona |
US8609733B2 (en) * | 2008-05-19 | 2013-12-17 | Massachusetts Institute Of Technology | Sensory-specific local anesthesia and prolonged duration local anesthesia |
US9072664B2 (en) * | 2008-05-22 | 2015-07-07 | 3M Innovative Properties Company | Process for manufacturing flowable powder drug compositions |
US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
SG10201608732VA (en) * | 2008-06-26 | 2016-12-29 | Anterios Inc | Dermal delivery |
DE102008037025C5 (de) | 2008-08-08 | 2016-07-07 | Jesalis Pharma Gmbh | Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform |
GB0818403D0 (en) * | 2008-10-08 | 2008-11-12 | Univ Leuven Kath | Aqueous electrophoretic deposition |
EP2334845A2 (en) * | 2008-10-06 | 2011-06-22 | Katholieke Universiteit Leuven K.U. Leuven R&D | Functional layers of biomolecules and living cells, and a novel system to produce such |
US20110200525A1 (en) * | 2008-10-09 | 2011-08-18 | Patz Jr Edward F | Vhh antibody fragments for use in the detection and treatment of cancer |
CA2782655A1 (en) | 2009-01-06 | 2010-07-15 | Pharmanova, Inc. | Nanoparticle pharmaceutical formulations |
EP2387394B1 (en) * | 2009-01-14 | 2018-05-02 | Corium International, Inc. | Transdermal administration of tamsulosin |
FR2945458B1 (fr) | 2009-05-13 | 2011-06-17 | Sanofi Aventis | Homogeneisation haute pression avec une valve en nitrure de silicium |
US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
US20100298335A1 (en) * | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and Methods for Ameliorating or Reducing Presbyopia |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
CN107669664B (zh) | 2009-05-29 | 2020-07-10 | 珍珠治疗公司 | 经呼吸递送活性剂的组合物及相关方法和*** |
JP5775071B2 (ja) | 2009-06-16 | 2015-09-09 | ファイザー・インク | アピキサバンの製剤形 |
US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
WO2011076208A2 (en) * | 2009-12-22 | 2011-06-30 | Leo Pharma A/S | Calcipotriol monohydrate nanocrystals |
TWI438009B (zh) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | 紫杉烷前-乳劑調配物及其製造與使用之方法 |
WO2011139899A2 (en) | 2010-05-03 | 2011-11-10 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
WO2011151418A2 (en) | 2010-06-02 | 2011-12-08 | Abbott Gmbh & Co. Kg | Nanosusupension formulation comprising a polydimethylsiloxane hydrophobic phase |
PL2651975T3 (pl) | 2010-12-14 | 2018-04-30 | Dso Nat Laboratories | Ludzkie przeciwciało monoklonalne o swoistości względem białka e wirusa denga serotypu 1 i jego zastosowania |
EP2583672A1 (en) | 2011-10-17 | 2013-04-24 | PharmaSol GmbH | Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process |
GB201118181D0 (en) | 2011-10-21 | 2011-12-07 | Jagotec Ag | Pharmaceutical compositions |
US9452107B2 (en) | 2012-04-16 | 2016-09-27 | New Jersey Institute Of Technology | Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents |
PL223346B1 (pl) * | 2012-09-28 | 2016-10-31 | E K A D Innotech Spółka Z Ograniczoną Odpowiedzialnością | Sposób i urządzenie do sterylizacji i homogenizacji produktów płynnych |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
KR102275109B1 (ko) | 2013-03-15 | 2021-07-07 | 펄 테라퓨틱스 인코포레이티드 | 미립자 결정질 재료를 컨디셔닝하는 방법 및 시스템 |
MX2015016058A (es) | 2013-05-22 | 2016-12-20 | Pearl Therapeutics Inc | Composiciones, metodos y sistemas para el suministro por via respiratoria de tres o mas agentes activos. |
WO2015183346A2 (en) | 2014-01-31 | 2015-12-03 | Washington University | Imaging and treatment of pathophysiologic conditions by cerenkov radiation |
US9974870B2 (en) | 2014-06-09 | 2018-05-22 | Washington University | Compositions and methods for treatment and imaging using nanoparticles |
EP3172238B1 (en) | 2014-07-23 | 2020-09-23 | Ohio State Innovation Foundation | Methods and compositions related to antibody fragments that bind to tumor-associated glycoprotein 72 (tag-72) |
EP3172222A4 (en) | 2014-07-24 | 2018-03-21 | Washington University | Compositions targeting radiation-induced molecules and methods of use thereof |
EP3206683A4 (en) | 2014-10-16 | 2018-06-13 | The Board of Trustees of the Leland Stanford Junior University | Novel methods, compounds, and compositions for anesthesia |
BR112018070960A2 (pt) * | 2016-04-13 | 2019-01-29 | Nortic Holdings Inc | formulação parenteral de nimodipina estável |
US10092553B2 (en) * | 2016-04-13 | 2018-10-09 | Nortic Holdings Inc. | Stable nimodipine parenteral formulation |
BR112019010131A2 (pt) | 2016-11-21 | 2019-10-08 | Eirion Therapeutics Inc | entrega transdérmica de agentes grandes |
US10226474B2 (en) | 2017-01-09 | 2019-03-12 | Temple University—Of The Commonwealth Sytem Of Higher Education | Methods and compositions for treatment of non-alcoholic steatohepatitis |
WO2018222583A1 (en) * | 2017-05-30 | 2018-12-06 | Rho Pharmaceuticals, Llc | In-vial deposition of a stable, sterile and crystalline o-acetyl salicylic acid (aspirin) |
WO2020121006A2 (en) | 2018-10-19 | 2020-06-18 | Innostudio Inc. | Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length |
US10973798B2 (en) * | 2018-12-23 | 2021-04-13 | SRM Institute of Science and Technology | Dispersion of formononetin solid lipid nanoparticles and process for its preparation |
US11788091B2 (en) | 2019-08-21 | 2023-10-17 | University Of Virginia Patent Foundation | Methods and compositions for diagnosing and treating prostate cancer based on long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth |
EP3884930A1 (en) | 2020-03-23 | 2021-09-29 | Bayer AG | Nano-dry-melting |
KR20240042436A (ko) | 2021-07-09 | 2024-04-02 | 아스트라제네카 파마수티컬스 엘피 | 에어로졸 약물 전달을 위한 조성물, 방법 및 시스템 |
WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
CN114099441A (zh) * | 2021-12-22 | 2022-03-01 | 金河牧星(重庆)生物科技有限公司 | 一种盐酸金霉素干混悬剂及其制备方法和应用 |
WO2023212191A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Combination of albuterol and budesonide for the treatment of asthma |
CN116270453B (zh) * | 2023-04-11 | 2024-03-12 | 江苏知原药业股份有限公司 | 一种联苯苄唑溶液剂及其制备工艺 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60150221A (ja) * | 1984-01-14 | 1985-08-07 | Sanee Denki Kk | 磁気ヘツド |
JPS60258110A (ja) * | 1984-06-05 | 1985-12-20 | Daigo Eiyou Kagaku Kk | 静脈注射可能なプロゲステロン乳化注射液 |
JPH0774145B2 (ja) * | 1986-12-15 | 1995-08-09 | 株式会社資生堂 | 結晶性薬物含有乳化組成物 |
NL194638C (nl) * | 1986-12-19 | 2002-10-04 | Novartis Ag | Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat. |
US4879308A (en) * | 1987-08-11 | 1989-11-07 | Lyphomed, Inc. | Aqueous nitroglycerin injection and manufacturing process |
DE68914929T2 (de) * | 1988-09-29 | 1994-08-11 | Shiseido Co Ltd | Emulgierte Zusammensetzung. |
JPH07121858B2 (ja) * | 1988-12-20 | 1995-12-25 | メディコントロール コーポレーション | 熱で脱水したエマルジョン組成物 |
US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
DE4140195C2 (de) * | 1991-12-05 | 1994-10-27 | Alfatec Pharma Gmbh | Pharmazeutisch applizierbares Nanosol und Verfahren zu seiner Herstellung |
IL101387A (en) * | 1992-03-26 | 1999-11-30 | Pharmos Ltd | Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets |
DE4217842A1 (de) * | 1992-05-29 | 1993-12-02 | Dietl Hans | Calciumantagonisten enthaltende pharmazeutische Zubereitung zur intravenösen und intrakoronaren Applikation sowie Verfahren zu ihrer Herstellung |
JPH06126143A (ja) * | 1992-10-14 | 1994-05-10 | Mitsubishi Heavy Ind Ltd | 凝集体含有液状混合物の分散方法 |
AU660852B2 (en) * | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
GB9226905D0 (en) * | 1992-12-24 | 1993-02-17 | Wellcome Found | Pharmaceutical preparation |
CA2091152C (en) * | 1993-03-05 | 2005-05-03 | Kirsten Westesen | Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof |
-
1994
- 1994-11-11 DE DE4440337A patent/DE4440337A1/de not_active Withdrawn
-
1995
- 1995-11-09 JP JP51571196A patent/JP3977418B2/ja not_active Expired - Lifetime
- 1995-11-09 CZ CZ19971426A patent/CZ293253B6/cs not_active IP Right Cessation
- 1995-11-09 SK SK584-97A patent/SK284541B6/sk not_active IP Right Cessation
- 1995-11-09 DE DE59510954T patent/DE59510954D1/de not_active Expired - Lifetime
- 1995-11-09 EE EE9700217A patent/EE9700217A/xx unknown
- 1995-11-09 CA CA002205046A patent/CA2205046C/en not_active Expired - Lifetime
- 1995-11-09 ES ES95938439T patent/ES2229242T3/es not_active Expired - Lifetime
- 1995-11-09 US US08/836,305 patent/US5858410A/en not_active Expired - Lifetime
- 1995-11-09 KR KR1019970703160A patent/KR100480447B1/ko not_active IP Right Cessation
- 1995-11-09 AU AU39827/95A patent/AU714978B2/en not_active Expired
- 1995-11-09 DE DE19581305T patent/DE19581305D2/de not_active Ceased
- 1995-11-09 PL PL95320085A patent/PL320085A1/xx unknown
- 1995-11-09 CN CNB951973010A patent/CN1210018C/zh not_active Expired - Lifetime
- 1995-11-09 AT AT95938439T patent/ATE278387T1/de not_active IP Right Cessation
- 1995-11-09 HU HU9702018A patent/HU228097B1/hu unknown
- 1995-11-09 WO PCT/EP1995/004401 patent/WO1996014830A1/de active IP Right Grant
- 1995-11-09 EP EP95938439A patent/EP0790821B1/de not_active Expired - Lifetime
-
1997
- 1997-05-09 NO NO19972142A patent/NO323143B1/no not_active IP Right Cessation
- 1997-05-09 FI FI971986A patent/FI119465B/fi not_active IP Right Cessation
- 1997-05-09 MX MX9703399A patent/MX9703399A/es unknown
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003504323A (ja) * | 1999-07-13 | 2003-02-04 | ファルマソル ゲーエムベーハー | 超微細マイクロ粒子およびナノ粒子の制御された製造方法。 |
JP2003527411A (ja) * | 2000-03-23 | 2003-09-16 | コラボレイティヴ・テクノロジーズ・インコーポレーテッド | 生理学上活性な成分を含有する高圧/高剪断分散物を調製する方法 |
JP2013209422A (ja) * | 2001-10-12 | 2013-10-10 | Elan Pharma Internatl Ltd | 即時放出および徐放特性を組み合わせて有する組成物 |
JP2017075182A (ja) * | 2001-10-12 | 2017-04-20 | エラン ファーマ インターナショナル,リミティド | 即時放出および徐放特性を組み合わせて有する組成物 |
WO2006073154A1 (ja) * | 2005-01-07 | 2006-07-13 | Eisai R&D Management Co., Ltd. | 医薬組成物及びその製造方法 |
JPWO2006073154A1 (ja) * | 2005-01-07 | 2008-06-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物及びその製造方法 |
JP2008536812A (ja) * | 2005-03-11 | 2008-09-11 | アボット ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 超微細サブミクロン懸濁液の製造方法 |
JP2008544963A (ja) * | 2005-06-29 | 2008-12-11 | ディーエスエム アイピー アセッツ ビー.ブイ. | イソフラボンナノ粒子およびその使用 |
JP2009503074A (ja) * | 2005-08-02 | 2009-01-29 | セラムオプテック インダストリーズ インコーポレーテッド | セルライトに対する光力学療法および美容法 |
JP2011513258A (ja) * | 2008-02-29 | 2011-04-28 | シュリフトハール ライナー | 改善された不純物プロファイル及び安全性を有し、吸入により投与される抗真菌薬を有するナノ懸濁液 |
JP2013501051A (ja) * | 2009-08-06 | 2013-01-10 | 株式会社エービーサイズ | ナノ粒子の溶液およびナノ粒子の懸濁物の両者を有する局所用薬学的調製物ならびに該調製物をもって急性疼痛および慢性疼痛を処置する方法 |
JP2013525385A (ja) * | 2010-04-27 | 2013-06-20 | 重▲慶▼莱美▲薬▼▲業▼股▲分▼有限公司 | ペクチン−アドリアマイシン共役体の凍結乾燥製剤および製造方法 |
WO2015068397A1 (ja) * | 2013-11-08 | 2015-05-14 | 株式会社アクティバスファーマ | マクロライド系抗菌剤のナノ微粒子を含有する水性懸濁液剤 |
US10792248B2 (en) | 2013-11-08 | 2020-10-06 | Activus Pharma Co., Ltd. | Aqueous suspension preparation comprising nanoparticles of macrolide antibacterial agent |
Also Published As
Publication number | Publication date |
---|---|
DE59510954D1 (de) | 2004-11-11 |
HUT77526A (hu) | 1998-05-28 |
NO972142L (no) | 1997-06-26 |
HU228097B1 (en) | 2012-10-29 |
KR970706795A (ko) | 1997-12-01 |
CZ293253B6 (cs) | 2004-03-17 |
FI971986A0 (fi) | 1997-05-09 |
CA2205046C (en) | 2002-05-14 |
CN1210018C (zh) | 2005-07-13 |
EP0790821B1 (de) | 2004-10-06 |
ES2229242T3 (es) | 2005-04-16 |
DE19581305D2 (de) | 1998-11-05 |
NO323143B1 (no) | 2007-01-08 |
ATE278387T1 (de) | 2004-10-15 |
CN1172428A (zh) | 1998-02-04 |
SK58497A3 (en) | 1997-11-05 |
CZ142697A3 (en) | 1997-10-15 |
US5858410A (en) | 1999-01-12 |
EE9700217A (et) | 1998-02-16 |
MX9703399A (es) | 1998-07-31 |
PL320085A1 (en) | 1997-09-15 |
CA2205046A1 (en) | 1996-05-23 |
FI119465B (fi) | 2008-11-28 |
JP3977418B2 (ja) | 2007-09-19 |
NO972142D0 (no) | 1997-05-09 |
SK284541B6 (sk) | 2005-06-02 |
KR100480447B1 (ko) | 2005-09-20 |
WO1996014830A1 (de) | 1996-05-23 |
AU3982795A (en) | 1996-06-06 |
AU714978B2 (en) | 2000-01-13 |
EP0790821A1 (de) | 1997-08-27 |
DE4440337A1 (de) | 1996-05-15 |
FI971986A (fi) | 1997-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH10508614A (ja) | 飽和溶解度と溶解速度を増大させた薬剤投与用ナノ懸濁液 | |
CA2623112C (en) | Method for producing ultrafine submicronic suspensions | |
US5785976A (en) | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | |
AU676279B2 (en) | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | |
US6207178B1 (en) | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof | |
CA2604770C (en) | Method for carefully producing ultrafine particle suspensions and ultrafine particles and use thereof | |
JP5539839B2 (ja) | 水不溶性物質のマイクロ粒子を製造するための組成物及び方法 | |
US6551619B1 (en) | Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation | |
CN1761454A (zh) | 小颗粒的制备方法 | |
Lee et al. | Particle size reduction | |
Sawant et al. | Drug nanocrystals: novel technique for delivery of poorly soluble drugs | |
Jayalakshmy et al. | Nanosuspension: A method for solubility enhancement | |
AU2762700A (en) | Pharmaceutical nanosuspensions for medicament administration as systems of increased saturation solubility and rate of solution | |
CA2113795A1 (en) | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060425 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060721 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060904 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061025 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070116 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070413 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070605 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070621 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100629 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110629 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120629 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120629 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130629 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |